Ad Hoc | Novartis

Media Release
Apr 28, 2020
Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19
Media Release
Apr 28, 2020
Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen
Media Release
Apr 28, 2020
Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
Media Release
May 06, 2020
Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14
Media Release
Jun 17, 2020
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
Media Release
Jun 25, 2020
Novartis Resolves Legacy FCPA Investigations
Media Release
Jul 03, 2020
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies
Media Release
Jul 21, 2020
Novartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.
Media Release
Jul 21, 2020
Novartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.
Media Release
Jul 21, 2020
Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.
Media Release
Aug 17, 2020
Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent
Media Release
Aug 20, 2020
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis